Table 4.
Oxyntomodulin-based therapeutic peptides.
| Peptide Name | AA Sequence | Development Stage | Reference |
|---|---|---|---|
| Native OXM | HSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNKNNIA | N/A | (245) |
| (D-Ser2)Oxm[mPEG-PAL] | H(DS)QGTFTSDYSKYLDSRRAQDFVQWLMNTKRNKNNIA-[mPEG-PAL] | Preclinical | (247) |
| Dogfish OXM | HSEGTFTSDYSKYMDNRRAKDFVQWLMSTKRNG | Preclinical | (248) |
| Ratfish OXM | HTDGIFSSDYSKYLDNRRTKDFVQWLLSTKRNGANT | Preclinical | (248) |
| [D-Ala2]GIP–Oxm | YDAEGTFISDYSKYLDSRRAQDFVQWLMNTKRNRNNIA | Preclinical | (184) |
| OX-SR | Structure N/A | Preclinical | (249) |
| LY3305677 | Structure N/A | Phase II-T2DM/Obesity (Eli Lilly) | (250, 251) |
| DualAG | HSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNKNNIA-Chol | Preclinical | (252) |
| GLPAG | HSEGTFTSDYSKYLDSRRAQDFVQWLMNTKRNKNNIA-Chol | Preclinical | (253) |
Amino acid sequences are provided in their single-letter abbreviation format. Modifications from native sequences are highlighted by red lettering. Current development stages, associated condition and holding companies (in brackets, where available) are provided for each. A “D” prefix before a residue indicates inclusion of the enantiomer for the naturally-occurring L form of the residue. “mPEG” indicates mini-polyethylene glycol addition. “PAL” indicates the addition of a palmitic fatty acid chain. “Chol” represents attachment of a human cholesterol fragment. “Structure N/A” represents a molecule for which the amino acid sequence has not been disclosed by authors.